Bilberry vs Lutein for eye health — which one for which complaint?
Both are sold as "eye vitamins" and frequently bundled together, but they do completely different things. Lutein (with its sibling zeaxanthin) is a macular pigment — it concentrates in the retina, filters blue light, and quenches oxidative damage at the macula. The AREDS2 trial confirmed lutein/zeaxanthin's role in slowing AMD progression. Bilberry is an anthocyanin extract with vasoactive and antioxidant effects on retinal microcirculation — its strongest evidence is in symptomatic complaints like asthenopia (digital eye strain), short-term contrast sensitivity, and adjuncts in some retinal vascular conditions.
Quick verdict
| Complaint | Better choice | Why |
|---|---|---|
| Age-related macular degeneration (AMD) — intermediate to advanced | Lutein + zeaxanthin (AREDS2) | Only intervention with multi-year RCT data slowing AMD progression in higher-risk eyes. |
| Digital eye strain / asthenopia from screens | Bilberry (often with lutein) | Small RCTs in office workers show subjective and objective improvements in eye strain and accommodative recovery. |
| Macular pigment optical density (MPOD) | Lutein + zeaxanthin | The only supplement that raises MPOD by mechanism — bilberry does not. |
| Diabetic retinopathy (early, adjunct) | Bilberry (modest) | Trial signals for capillary fragility and microvascular endpoints; not a substitute for tight glycaemic control. |
| Night vision / dark adaptation | Neither (mostly) | The wartime RAF bilberry-pilot story is folklore; modern trials do not confirm night-vision improvement in healthy eyes. |
| Glaucoma (adjunct to drops) | Bilberry (small case) | Small trials of standardised anthocyanin extracts have shown adjunct effects in some glaucoma cohorts; lutein has weaker data here. |
How they compare on the things that matter
Mechanism — pigment vs polyphenol
Lutein and zeaxanthin are xanthophyll carotenoids that deposit specifically in the macula, the central retinal area responsible for high-acuity vision. They quench reactive oxygen species generated by short-wavelength visible light and act as an optical filter for blue light reaching photoreceptors. Their concentration in retinal tissue, expressed as macular pigment optical density (MPOD), is the most-studied biomarker for "more pigment = more protection" in long-term AMD risk.
Bilberry (Vaccinium myrtillus) is a wild Nordic berry whose blue-purple skin is rich in anthocyanins (typically standardised to 25–36% anthocyanosides). Anthocyanins do not deposit in the macula. They act systemically: improving capillary integrity, modulating endothelial nitric oxide, and contributing antioxidant activity to retinal microcirculation. The relevant outcomes are vascular and accommodative rather than pigment-density.
Evidence base by clinical endpoint
- AMD progression: AREDS2 (NIH-funded, ~4,000 participants, 5-year follow-up) substituted lutein/zeaxanthin for beta-carotene and confirmed reduced progression to advanced AMD in higher-risk eyes — particularly in participants with low dietary lutein intake. Bilberry has no AMD progression data of comparable weight.
- Digital eye strain (asthenopia): Several small Japanese and European RCTs of standardised bilberry extract (Mirtoselect-type, 160 mg b.i.d.) have shown reductions in subjective eye fatigue and improvements in accommodative recovery in VDT workers. Lutein has parallel but smaller signals here.
- Cataract prevention: Higher dietary intake of lutein and other carotenoids has prospective epidemiological associations with reduced cataract incidence; supplementation trial data are weaker but not negative.
- Diabetic retinopathy: Bilberry has small trial signals on microvascular endpoints in early DR as an adjunct to standard care.
- Glaucoma: Small trials of standardised anthocyanin extract have shown small adjunct improvements in visual field and ocular blood flow.
- Healthy eyes / general antioxidant claims: Both are reasonable as part of a varied diet (kale, spinach, eggs for lutein; berries for anthocyanins). Supplements are most justified when intake is low.
Dose and form
For lutein: 10 mg/day lutein plus 2 mg/day zeaxanthin (the AREDS2 doses) is the well-evidenced ratio. Bound to a fat-containing meal because xanthophylls are fat-soluble. Marigold extract is the predominant commercial source; FloraGlo and Lutemax 2020 are the most-studied branded ingredients. Effect on MPOD plateaus over months — this is not a same-day supplement.
For bilberry: 160 mg twice daily of standardised extract (typically Mirtoselect, 36% anthocyanosides), or equivalent — about 115 mg anthocyanosides/day total. Effects on eye strain are reported within 4–6 weeks; the supplement is not acutely active. Generic non-standardised bilberry powders vary enormously in anthocyanin content and are not interchangeable with the standardised material used in trials.
Safety
Lutein is well-tolerated. The largest dietary-supplement safety database (AREDS2) found no serious safety signals at 10 mg/day over five years. Very high intakes (often via combined supplement + diet over years) can transiently elevate skin carotenoid concentrations — a benign cosmetic effect.
Bilberry is well-tolerated at trial doses. The theoretical concern is additive antiplatelet effect with anticoagulants (anthocyanins have mild antiplatelet activity); users on warfarin or DOACs should mention bilberry to the prescribing clinician. Pregnancy and lactation safety data at supplemental doses are limited.
What the price difference buys you
Lutein 10 mg/day (FloraGlo or Lutemax 2020) runs $0.15–0.30/day. Standardised bilberry (Mirtoselect-type) at trial doses runs $0.30–0.60/day. Combination "eye health" products often include sub-therapeutic doses of each — read the doses carefully against the AREDS2 lutein/zeaxanthin and Mirtoselect-equivalent bilberry doses above.
Who should skip each
Lutein has very few contraindications. Smokers should still avoid high-dose beta-carotene; lutein does not share that risk. Patients on certain cholesterol-lowering medications absorb fat-soluble carotenoids better with statins on board, not worse.
Bilberry should be approached cautiously in users on anticoagulants or antiplatelets, in pregnancy/lactation (limited data), and discontinued 2 weeks before scheduled surgery due to the theoretical bleeding risk.
What we'd actually buy
For someone over 50 with a family history of AMD or with intermediate AMD: an AREDS2-formula product (lutein 10 mg + zeaxanthin 2 mg, plus zinc, copper, vitamins C and E in the AREDS2 doses). Take with a fat-containing meal.
For screen-heavy office workers reporting eye fatigue, blurry vision at the end of the day, or accommodative discomfort: standardised bilberry (Mirtoselect-type) 160 mg twice daily, often paired with separate lutein for the long-term retinal pigment effect.
Sources
- Chew EY, et al. Long-term outcomes of adding lutein/zeaxanthin and omega-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 report 28. JAMA Ophthalmol. 2022;140(7):692–698. PMID: 35679026
- Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the AREDS2 randomized clinical trial. JAMA. 2013;309(19):2005–2015. PMID: 23644932
- Kawabata F, Tsuji T. Effects of dietary supplementation with a combination of fish oil, bilberry extract, and lutein on subjective symptoms of asthenopia in humans. Biomed Res. 2011;32(6):387–393. PMID: 22199130
- Riva A, et al. The effect of a natural, standardized bilberry extract (Mirtoselect®) in dry eye: a randomized clinical evaluation. Eur Rev Med Pharmacol Sci. 2017;21(10):2518–2525. PMID: 28617543
- Shim SH, et al. Ginkgo biloba extract and bilberry anthocyanins improve visual function in patients with normal tension glaucoma. J Med Food. 2012;15(9):818–823. PMID: 22870951
- Kalt W, et al. Recent research on the health benefits of blueberries and their anthocyanins. Adv Nutr. 2020;11(2):224–236. PMID: 31329250